256 related articles for article (PubMed ID: 18639872)
1. Survival advantage of neonatal CNS gene transfer for late infantile neuronal ceroid lipofuscinosis.
Sondhi D; Peterson DA; Edelstein AM; del Fierro K; Hackett NR; Crystal RG
Exp Neurol; 2008 Sep; 213(1):18-27. PubMed ID: 18639872
[TBL] [Abstract][Full Text] [Related]
2. Long-term expression and safety of administration of AAVrh.10hCLN2 to the brain of rats and nonhuman primates for the treatment of late infantile neuronal ceroid lipofuscinosis.
Sondhi D; Johnson L; Purpura K; Monette S; Souweidane MM; Kaplitt MG; Kosofsky B; Yohay K; Ballon D; Dyke J; Kaminksy SM; Hackett NR; Crystal RG
Hum Gene Ther Methods; 2012 Oct; 23(5):324-35. PubMed ID: 23131032
[TBL] [Abstract][Full Text] [Related]
3. Enhanced survival of the LINCL mouse following CLN2 gene transfer using the rh.10 rhesus macaque-derived adeno-associated virus vector.
Sondhi D; Hackett NR; Peterson DA; Stratton J; Baad M; Travis KM; Wilson JM; Crystal RG
Mol Ther; 2007 Mar; 15(3):481-91. PubMed ID: 17180118
[TBL] [Abstract][Full Text] [Related]
4. Clinical protocol. Administration of a replication-deficient adeno-associated virus gene transfer vector expressing the human CLN2 cDNA to the brain of children with late infantile neuronal ceroid lipofuscinosis.
Crystal RG; Sondhi D; Hackett NR; Kaminsky SM; Worgall S; Stieg P; Souweidane M; Hosain S; Heier L; Ballon D; Dinner M; Wisniewski K; Kaplitt M; Greenwald BM; Howell JD; Strybing K; Dyke J; Voss H
Hum Gene Ther; 2004 Nov; 15(11):1131-54. PubMed ID: 15610613
[TBL] [Abstract][Full Text] [Related]
5. AAV2-mediated CLN2 gene transfer to rodent and non-human primate brain results in long-term TPP-I expression compatible with therapy for LINCL.
Sondhi D; Peterson DA; Giannaris EL; Sanders CT; Mendez BS; De B; Rostkowski AB; Blanchard B; Bjugstad K; Sladek JR; Redmond DE; Leopold PL; Kaminsky SM; Hackett NR; Crystal RG
Gene Ther; 2005 Nov; 12(22):1618-32. PubMed ID: 16052206
[TBL] [Abstract][Full Text] [Related]
6. Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA.
Worgall S; Sondhi D; Hackett NR; Kosofsky B; Kekatpure MV; Neyzi N; Dyke JP; Ballon D; Heier L; Greenwald BM; Christos P; Mazumdar M; Souweidane MM; Kaplitt MG; Crystal RG
Hum Gene Ther; 2008 May; 19(5):463-74. PubMed ID: 18473686
[TBL] [Abstract][Full Text] [Related]
7. Slowing late infantile Batten disease by direct brain parenchymal administration of a rh.10 adeno-associated virus expressing
Sondhi D; Kaminsky SM; Hackett NR; Pagovich OE; Rosenberg JB; De BP; Chen A; Van de Graaf B; Mezey JG; Mammen GW; Mancenido D; Xu F; Kosofsky B; Yohay K; Worgall S; Kaner RJ; Souwedaine M; Greenwald BM; Kaplitt M; Dyke JP; Ballon DJ; Heier LA; Kiss S; Crystal RG
Sci Transl Med; 2020 Dec; 12(572):. PubMed ID: 33268510
[TBL] [Abstract][Full Text] [Related]
8. Partial correction of the CNS lysosomal storage defect in a mouse model of juvenile neuronal ceroid lipofuscinosis by neonatal CNS administration of an adeno-associated virus serotype rh.10 vector expressing the human CLN3 gene.
Sondhi D; Scott EC; Chen A; Hackett NR; Wong AM; Kubiak A; Nelvagal HR; Pearse Y; Cotman SL; Cooper JD; Crystal RG
Hum Gene Ther; 2014 Mar; 25(3):223-39. PubMed ID: 24372003
[TBL] [Abstract][Full Text] [Related]
9. Assessment of Safety and Biodistribution of AAVrh.10hCLN2 Following Intracisternal Administration in Nonhuman Primates for the Treatment of CLN2 Batten Disease.
De BP; Rosenberg JB; Selvan N; Wilson I; Yusufzai N; Greco A; Kaminsky SM; Heier LA; Ricart Arbona RJ; Miranda IC; Monette S; Nair A; Khanna R; Crystal RG; Sondhi D
Hum Gene Ther; 2023 Sep; 34(17-18):905-916. PubMed ID: 37624739
[TBL] [Abstract][Full Text] [Related]
10. Residual levels of tripeptidyl-peptidase I activity dramatically ameliorate disease in late-infantile neuronal ceroid lipofuscinosis.
Sleat DE; El-Banna M; Sohar I; Kim KH; Dobrenis K; Walkley SU; Lobel P
Mol Genet Metab; 2008 Jun; 94(2):222-33. PubMed ID: 18343701
[TBL] [Abstract][Full Text] [Related]
11. Intracranial delivery of CLN2 reduces brain pathology in a mouse model of classical late infantile neuronal ceroid lipofuscinosis.
Passini MA; Dodge JC; Bu J; Yang W; Zhao Q; Sondhi D; Hackett NR; Kaminsky SM; Mao Q; Shihabuddin LS; Cheng SH; Sleat DE; Stewart GR; Davidson BL; Lobel P; Crystal RG
J Neurosci; 2006 Feb; 26(5):1334-42. PubMed ID: 16452657
[TBL] [Abstract][Full Text] [Related]
12. A mouse model of classical late-infantile neuronal ceroid lipofuscinosis based on targeted disruption of the CLN2 gene results in a loss of tripeptidyl-peptidase I activity and progressive neurodegeneration.
Sleat DE; Wiseman JA; El-Banna M; Kim KH; Mao Q; Price S; Macauley SL; Sidman RL; Shen MM; Zhao Q; Passini MA; Davidson BL; Stewart GR; Lobel P
J Neurosci; 2004 Oct; 24(41):9117-26. PubMed ID: 15483130
[TBL] [Abstract][Full Text] [Related]
13. Intraventricular enzyme replacement improves disease phenotypes in a mouse model of late infantile neuronal ceroid lipofuscinosis.
Chang M; Cooper JD; Sleat DE; Cheng SH; Dodge JC; Passini MA; Lobel P; Davidson BL
Mol Ther; 2008 Apr; 16(4):649-56. PubMed ID: 18362923
[TBL] [Abstract][Full Text] [Related]
14. Dipeptidyl-peptidase I does not functionally compensate for the loss of tripeptidyl-peptidase I in the neurodegenerative disease late-infantile neuronal ceroid lipofuscinosis.
Kim KH; Pham CT; Sleat DE; Lobel P
Biochem J; 2008 Oct; 415(2):225-32. PubMed ID: 18570628
[TBL] [Abstract][Full Text] [Related]
15. Timing of therapeutic intervention determines functional and survival outcomes in a mouse model of late infantile batten disease.
Cabrera-Salazar MA; Roskelley EM; Bu J; Hodges BL; Yew N; Dodge JC; Shihabuddin LS; Sohar I; Sleat DE; Scheule RK; Davidson BL; Cheng SH; Lobel P; Passini MA
Mol Ther; 2007 Oct; 15(10):1782-8. PubMed ID: 17637720
[TBL] [Abstract][Full Text] [Related]
16. Enzyme replacement therapy attenuates disease progression in a canine model of late-infantile neuronal ceroid lipofuscinosis (CLN2 disease).
Katz ML; Coates JR; Sibigtroth CM; Taylor JD; Carpentier M; Young WM; Wininger FA; Kennedy D; Vuillemenot BR; O'Neill CA
J Neurosci Res; 2014 Nov; 92(11):1591-8. PubMed ID: 24938720
[TBL] [Abstract][Full Text] [Related]
17. Safety of direct administration of AAV2(CU)hCLN2, a candidate treatment for the central nervous system manifestations of late infantile neuronal ceroid lipofuscinosis, to the brain of rats and nonhuman primates.
Hackett NR; Redmond DE; Sondhi D; Giannaris EL; Vassallo E; Stratton J; Qiu J; Kaminsky SM; Lesser ML; Fisch GS; Rouselle SD; Crystal RG
Hum Gene Ther; 2005 Dec; 16(12):1484-503. PubMed ID: 16390279
[TBL] [Abstract][Full Text] [Related]
18. CLN2 Disease (Classic Late Infantile Neuronal Ceroid Lipofuscinosis).
Kohlschütter A; Schulz A
Pediatr Endocrinol Rev; 2016 Jun; 13 Suppl 1():682-8. PubMed ID: 27491216
[TBL] [Abstract][Full Text] [Related]
19. Upregulation of tripeptidyl-peptidase 1 by 3-hydroxy-(2,2)-dimethyl butyrate, a brain endogenous ligand of PPARα: Implications for late-infantile Batten disease therapy.
Chakrabarti S; Chandra S; Roy A; Dasarathi S; Kundu M; Pahan K
Neurobiol Dis; 2019 Jul; 127():362-373. PubMed ID: 30928643
[TBL] [Abstract][Full Text] [Related]
20. Biochemical characterization of a lysosomal protease deficient in classical late infantile neuronal ceroid lipofuscinosis (LINCL) and development of an enzyme-based assay for diagnosis and exclusion of LINCL in human specimens and animal models.
Sohar I; Sleat DE; Jadot M; Lobel P
J Neurochem; 1999 Aug; 73(2):700-11. PubMed ID: 10428067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
